title: Bone marrow transplantation in thalassaemia patients in Shiraz, Islamic Republic of Iran.
abstract: We report the results of allogeneic bone marrow transplantation in 26 female and 37 male patients with beta-thalassaemia major (age range: 2-17 years), performed at Namazi Hospital over the period 1992-99. In all cases, standard conditioning and immunosuppressive regimens were employed. Currently, 50 patients remain thalassaemia-free, 9 of whom have developed chronic graft-versus-host disease. There were 8 deaths among the 13 unsuccessful transplant cases: 4 due to acute uncontrollable graft-versus-host disease, and 4 to non-transplant-related causes such as hypoglycaemia, hypersensitivity reactions and advanced disease. We conclude that allogeneic bone marrow transplantation is an effective therapy for the treatment of beta-thalassaemia major, particularly for patients classified as classes I and II.
authors.affiliation: Department of Internal Medicine, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Islamic Republic of Iran.
authors.forename: H N
authors.initials: HN
authors.lastname: Khojasteh
authors.forename: M
authors.initials: M
authors.lastname: Zakerinia
authors.forename: M
authors.initials: M
authors.lastname: Ramzi
authors.forename: M
authors.initials: M
authors.lastname: Haghshenas
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000276:immunology / Q000379:methods / Q000401:mortality; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology / Q000209:etiology; D006086:Graft vs Host Disease / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D007003:Hypoglycemia / Q000453:epidemiology / Q000209:etiology; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007165:Immunosuppression Therapy / Q000379:methods; D007492:Iran / Q000453:epidemiology; D008297:Male; D018579:Patient Selection; D011239:Prednisolone / Q000627:therapeutic use; D018805:Sepsis / Q000453:epidemiology / Q000209:etiology; D012720:Severity of Illness Index; D015996:Survival Rate; D019172:Transplantation Conditioning / Q000379:methods; D016896:Treatment Outcome; D017086:beta-Thalassemia / Q000145:classification / Q000276:immunology / Q000628:therapy*
chemical_list: D000893:Anti-Inflammatory Agents; D016756:Immunoglobulins, Intravenous; D011239:Prednisolone